Sk Shehan Hossain | Biochemistry, Genetics and Molecular Biology | Young Scientist Award

Published on by Academic Excellence

Young Scientist Award

Sk Shehan Hossain
Regional Institute of Biotechnology, India

Sk Shehan Hossain
Affiliation Regional Institute of Biotechnology
Country India
Documents 3
Subject Area Biochemistry, Genetics and Molecular Biology
Event International Academic Excellence Awards
ORCID 0009-0004-7544-4607

Sk Shehan Hossain is an emerging researcher affiliated with the Regional Institute of Biotechnology, India. His scholarly activities are centered on microbiology, molecular biology, bioinformatics, and computational approaches in biological sciences. Through a combination of molecular characterization and in silico investigations, he has contributed to the documentation of microbial genetic resources and the exploration of biologically active compounds. His research profile demonstrates early-stage scientific productivity supported by publicly accessible datasets and preprint dissemination platforms.[1][3]

Abstract

This article presents an overview of the research profile of Sk Shehan Hossain in the context of the Young Scientist Award. His work includes microbial genetic identification through 16S ribosomal RNA sequencing and computational evaluation of naturally occurring compounds with potential biomedical relevance. The combination of laboratory-supported microbial studies and bioinformatics-based investigations reflects an interdisciplinary approach aligned with contemporary life science research.[2][3]

Keywords

Microbiology, Molecular Biology, Bacillus Species, 16S rRNA Sequencing, Bioinformatics, Computational Biology, Acetylcholinesterase Inhibitor, Biotechnology.

Introduction

Modern biotechnology increasingly integrates experimental and computational methodologies to address biological questions. Researchers working in this domain contribute to microbial characterization, genomic documentation, and the identification of bioactive compounds. Sk Shehan Hossain’s recent works reflect these trends through publicly archived sequence records and computational studies examining therapeutic potential in natural products.[2][3]

Research Profile

The research activities of Sk Shehan Hossain focus on biological characterization, microbial taxonomy, and computational analysis of biologically significant compounds. His profile demonstrates engagement with open scientific repositories and the dissemination of research findings through internationally accessible platforms. The available publications indicate a commitment to generating foundational scientific knowledge within biotechnology and molecular biology.[1]

Research Contributions

  • Documentation of Bacillus cereus strain AKANKSHYAYTB through 16S rRNA gene sequence submission.
  • Identification and reporting of Bacillus safensis strain BISAMLANWB genetic sequence data.
  • Computational evaluation of suaveolic acid as a potential acetylcholinesterase inhibitor.
  • Promotion of open scientific data accessibility through recognized repositories.

Publications

  1. Bacillus cereus strain AKANKSHYAYTB 16S ribosomal RNA gene, partial sequence (NCBI GenBank, 2026).
  2. Bacillus safensis strain BISAMLANWB 16S ribosomal RNA gene, partial sequence (NCBI GenBank, 2026).
  3. In Silico Investigation of Suaveolic Acid from Mesosphaerum suaveolens as an Acetylcholinesterase Inhibitor (Preprint, 2026).

Research Impact

The documented outputs contribute to publicly available scientific resources used by researchers in microbiology and biotechnology. Sequence submissions enrich genomic databases, while computational investigations provide preliminary insights that may support future experimental validation. Such contributions are valuable for advancing reproducibility, accessibility, and collaborative research within the life sciences.[2][3]

Award Suitability

The Young Scientist Award recognizes emerging researchers who demonstrate scientific promise and meaningful scholarly engagement. Based on the available record, Sk Shehan Hossain has established an early research portfolio encompassing molecular biology, microbial genetics, and computational biotechnology. His documented contributions and commitment to open scientific dissemination align with the objectives commonly associated with early-career research recognition programs.[4]

Conclusion

Sk Shehan Hossain represents a developing researcher whose work integrates microbial characterization and computational biological analysis. Through sequence database contributions and bioinformatics-based investigations, he has demonstrated engagement with contemporary scientific methodologies. His academic activities reflect the characteristics of an emerging scientist contributing to biotechnology and molecular biology research.

References

  1. Elsevier. (n.d.). ORCID author details: Sk Shehan Hossain.
  2. NCBI GenBank. (2026). Bacillus cereus strain AKANKSHYAYTB 16S ribosomal RNA gene, partial sequence.
    https://www.ncbi.nlm.nih.gov/nuccore/PZ619927
  3. Zenodo. (2026). In Silico Investigation of Suaveolic Acid from Mesosphaerum suaveolens as an Acetylcholinesterase Inhibitor.
    https://doi.org/10.5281/ZENODO.18837832
  4. International Academic Excellence Awards. (n.d.). Award recognition framework and evaluation criteria.
    academicexcellenceawards.com
  5. NCBI GenBank. (2026). Bacillus safensis strain BISAMLANWB 16S ribosomal RNA gene, partial sequence.
    https://www.ncbi.nlm.nih.gov/nuccore/PZ619164.1/

Priyanka Singh | Pharmacology | Women Researcher Award

Published on by Academic Excellence

Dr. Priyanka Singh | Pharmacology | Women Researcher Award

Technical University of Denmark | Denmark

Dr. Priyanka Singh is a Senior Researcher and Co-Principal Investigator at the Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark. With a PhD in Biomedical Science from Kyung Hee University, South Korea, and advanced training in microbiology from India, she has built an internationally recognized career at the intersection of nanomedicine, sustainable materials engineering, and translational therapeutics. Her research focuses on developing green nanomaterials, metallic nanoparticles, and chitosan-based systems for cancer therapy and combating antimicrobial resistance, particularly biofilm-associated infections. At DTU, she has played a pivotal role in establishing sustainable nanotherapeutic platforms, demonstrating efficacy in both advanced in vitro models and in vivo systems. She leads projects within major EU-funded consortia and has contributed to cutting-edge programs such as Marie Curie ITN and NordForsk collaborations. Dr. Singh has authored 88 peer-reviewed publications, garnering over 9,500 citations and an h-index of 46, earning recognition among the world’s top 2% scientists by Stanford University. Her scientific leadership extends to mentoring PhD and postdoctoral researchers, coordinating interdisciplinary projects, and promoting global collaboration as Regional Coordinator for IEEE Women in Nanotechnology (WIN). Her contributions have been recognized through multiple awards, including the Most Cited Paper Award in Nanobiotechnology (2024) and prestigious fellowships from Lundbeckfonden and the EU Marie Curie program. Beyond academia, she actively engages in science communication, mentorship, and editorial roles across leading journals. Driven by a vision to advance sustainable nanotherapeutics, Dr. Singh continues to pioneer research bridging nanotechnology, medicine, and sustainability.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

  • Biological synthesis of nanoparticles from plants and microorganisms  – P Singh, YJ Kim, D Zhang, DC Yang, Trends in Biotechnology 34(7), 588-599, 2016.

  • Gold nanoparticles in diagnostics and therapeutics for human cancer  – P Singh, S Pandit, V Mokkapati, A Garg, V Ravikumar, I Mijakovic, International Journal of Molecular Sciences 19(7), 1979, 2018.

  • Green synthesis of silver nanoparticles by Bacillus methylotrophicus, and their antimicrobial activity  – C Wang, YJ Kim, P Singh, R Mathiyalagan, Y Jin, DC Yang, Artificial Cells, Nanomedicine, and Biotechnology 44(4), 1127-1132, 2016.

  • Interactions of gold and silver nanoparticles with bacterial biofilms: Molecular interactions behind inhibition and resistance  – AS Joshi, P Singh, I Mijakovic, International Journal of Molecular Sciences 21(20), 7658, 2020.

  • Ecofriendly synthesis of silver and gold nanoparticles by Euphrasia officinalis leaf extract and its biomedical applications – H Singh, J Du, P Singh, TH Yi, Artificial Cells, Nanomedicine, and Biotechnology 46(6), 1163-1170, 2018.

Inamul Hasan Madar | Medicine | Outstanding Scientist Award

Published on by Academic Excellence

Prof. Dr. Inamul Hasan Madar | Medicine | Outstanding Scientist Award

Prof. Dr. Inamul Hasan Madar | Medicine | Yenepoya Universtiy |India

Dr. Inamul Hasan Madar is a distinguished researcher and educator in the field of biochemistry with a specialization in oncology proteogenomics. He earned his PhD from Korea University, a globally ranked institution, and has since developed extensive expertise in cancer genomics, multiomics integration, and bioinformatics. With a strong commitment to advancing medical research, Dr. Madar has served as an adjunct faculty at Saveetha Medical College (SIMATS), where he has mentored PhD, MD, MBBS, and MSc students in cutting-edge biomedical sciences. His international research experience includes appointments at Korea University and Hanyang University in South Korea, where he contributed to high-impact oncology projects. As Director and Lead of Canary Oncoceutics India, he has bridged the gap between research and industry by leading innovative onco-therapeutic initiatives. Widely published in top-tier journals, Dr. Madar has also served as a reviewer for international journals and as a member of prestigious scientific societies worldwide.

Author profile

Orcid

Education

Dr. Madar’s academic journey reflects a deep pursuit of excellence in biomedical sciences. He earned his PhD in Biochemistry, specializing in Onco-Proteogenomics, from Korea University, Seoul, ranked among the top global universities. His doctoral work focused on proteogenomic profiling and cancer biomarker discovery, positioning him at the forefront of precision oncology. Before this, he pursued advanced training in bioinformatics, molecular biology, and proteomics, equipping him with multidisciplinary skills to tackle complex biomedical challenges. His postgraduate education emphasized molecular diagnostics and computational approaches, while his undergraduate studies laid the foundation in biochemistry and clinical applications. Dr. Madar has also completed specialized training programs in next-generation sequencing (NGS), computational modeling, molecular docking, and drug discovery pipelines. Furthermore, he has been actively engaged in faculty development programs, including pedagogy training for undergraduate teaching in life sciences and biotechnology. This comprehensive educational background underscores his ability to combine research innovation with academic excellence.

Experience

Dr. Madar’s professional experience spans academia, research, and industry. He currently serves as Adjunct Faculty at Saveetha Medical College, SIMATS, where he mentors MBBS, MD, MSc, MPhil, and PhD students in research methodologies, cancer biology, and bioinformatics. He is also Director and Lead (Marketing) at Canary Oncoceutics India, overseeing translational oncology research and innovation in oncoceutical product development. Internationally, he worked as a Visiting Scientist at Korea University, specializing in proteogenomics, and as a Researcher at Hanyang University, Seoul, in bioengineering. In India, his previous roles include Scientist & Course Coordinator at Biocuration, where he designed genomics and drug development modules, and Junior Scientist at iPro Technologies. He has also contributed as a guest lecturer at Bharathidasan University, training future biochemists. His expertise extends to designing computational pipelines, analyzing multiomics datasets, and leading cross-disciplinary projects that bridge laboratory science and clinical application, particularly in cancer therapeutics and biomarker discovery.

Awards and Honors

Dr. Inamul Hasan Madar has received widespread recognition for his contributions to biomedical research and education. His publications in high-impact journals such as Nature Cancer, Oncotarget, Briefings in Bioinformatics, and Molecular Cancer have positioned him among leading voices in proteogenomics and cancer research. He has served as a peer reviewer for several prestigious journals, including Nature’s Scientific Reports, Frontiers in Oncology, BMC Medical Genomics, and Journal of Translational Medicine. He has been actively involved in international professional societies, including the American Association of Cancer Research (AACR), American Society for Biochemistry and Molecular Biology (ASBMB), International Society of Computational Biology (ISCB), and South African and Korean Mass Spectrometry Societies. His leadership roles include serving as Vice President of ISCB-RSG India, demonstrating his dedication to strengthening scientific networks. He has also mentored numerous graduate and medical students, guiding them to publish impactful research, file patents, and develop translational medical applications.

Research Focus

Dr. Madar’s research focus lies at the intersection of cancer genomics, proteogenomics, and computational biology. He specializes in integrating multiomics datasets to identify novel biomarkers and therapeutic targets for treatment-resistant cancers, particularly cervical, prostate, and oral squamous cell carcinoma. His expertise in next-generation sequencing (RNA-Seq, Exome-Seq) and bioinformatics has enabled him to develop innovative pipelines for cancer biomarker discovery, molecular subtyping, and clinical variant interpretation. Beyond oncology, he has contributed to research in neurobiology, metabolic disorders, cardiovascular protection, and bioactive peptides against diabetes and obesity. His translational approach emphasizes the “bench-to-bedside” concept, applying computational models and molecular profiling to guide precision medicine strategies. Dr. Madar has also explored theranostic targets, signaling networks, and novel oncoceutical formulations. His interdisciplinary collaborations with international research groups have advanced drug design, CAR-T therapy applications, and personalized treatment strategies, positioning him as a pioneer in cancer research and translational medicine.

Publications

  • Correction to: Proteogenomic characterization of molecular and cellular targets for treatment-resistant cervical cancers.

  • Molecular analysis of HPV16 and HPV18 oncogenes in oral squamous cell carcinoma.

  • Proteogenomic characterization of treatment-resistant subtypes in cervical cancers.

  • Theranostic Target NSUN2 uncovered with systematic assembly of 805 datasets.

  • Unravelling the phosphoregulatory network of PKC-delta (PKC-δ).

  • BDNF-TrkB signalling: A neurotrophic pathway to cardiovascular protection.

  • Physiological activities of bioactive peptides against diabetes and obesity.

  • SGLT2 inhibitors as dual therapeutic targets for cardiovascular and renal health.

  • Biobased nanomaterials and rhizobacteria for sustainable plant growth.

  • CAR-T therapy in oral squamous cell carcinoma: Current innovations and future prospects.

Conclusion

Dr. Inamul Hasan Madar exemplifies excellence in translational medicine, combining cutting-edge cancer research with dedicated academic mentorship. His impactful publications, international collaborations, and leadership in oncology research position him as a transformative figure in biomedical sciences. Through his expertise in proteogenomics and bioinformatics, he continues to advance precision medicine while inspiring the next generation of medical researchers.